Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07248144 |
Synonyms | |
Therapy Description |
PF-07248144 selectively inhibits KAT6, a histone acetyltransferase regulating gene expression, which may lead to tumor growth inhibition (J Clin Oncol 41, 2023 (suppl 16; abstr 1054)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07248144 | PF07248144|PF 07248144 | PF-07248144 selectively inhibits KAT6, a histone acetyltransferase regulating gene expression, which may lead to tumor growth inhibition (J Clin Oncol 41, 2023 (suppl 16; abstr 1054)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04606446 | Phase I | PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) | Recruiting | USA | AUS | 3 |